What is HC Wainwright's Estimate for Evolus FY2025 Earnings?

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 EPS estimates for Evolus in a research report issued to clients and investors on Thursday, April 10th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.28) per share for the year, down from their previous forecast of ($0.23). HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.61) per share.

Several other research analysts have also recently weighed in on EOLS. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. BTIG Research began coverage on Evolus in a research report on Thursday. They set a "buy" rating and a $21.00 price target for the company. Finally, Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Evolus presently has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Stock Up 6.7 %

NASDAQ EOLS traded up $0.68 on Monday, reaching $10.79. The company had a trading volume of 1,051,617 shares, compared to its average volume of 660,105. The company's fifty day moving average is $12.62 and its 200-day moving average is $13.14. The firm has a market capitalization of $686.10 million, a price-to-earnings ratio of -11.86 and a beta of 0.97. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus has a 1-year low of $8.67 and a 1-year high of $17.82.

Insider Buying and Selling

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,575 shares of company stock worth $794,369. Corporate insiders own 6.10% of the company's stock.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new position in shares of Evolus during the 4th quarter worth approximately $49,000. IFP Advisors Inc increased its holdings in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after purchasing an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus during the 4th quarter worth about $106,000. Rafferty Asset Management LLC bought a new stake in shares of Evolus during the 4th quarter worth about $115,000. Finally, Quantbot Technologies LP acquired a new position in Evolus in the 4th quarter valued at about $118,000. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.